Zygomycetes infections in pediatric hematologyoncology patients: A case series and review of the literature

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 12, 2009, Pages 911-919

  Dehority, Walter ^a   Willert, Jennifer ^b   Pong, Alice ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Immunosuppresion; Malignancy; Mucor; Neutropenia; Zygomycetes

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; MICAFUNGIN; POSACONAZOLE; STEROID; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APLASTIC ANEMIA; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DEBRIDEMENT; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GASTROINTESTINAL DISEASE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HYPERBARIC OXYGEN; IMMUNOCOMPROMISED PATIENT; IRON CHELATION; LUNG DISEASE; LYMPHOMA; MACROPHAGE FUNCTION; MALE; MORTALITY; MOUSE; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RHINOSINUSITIS; RISK FACTOR; STEROID THERAPY; SURVIVAL RATE; ZYGOMYCETES; BLOOD DISEASE; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; PARANASAL SINUS DISEASE; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; REVIEW; ZYGOMYCOSIS;

ADOLESCENT; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; CHILD; CHILD, PRESCHOOL; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; PARANASAL SINUS DISEASES; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; SURVIVAL RATE; YOUNG ADULT; ZYGOMYCOSIS;

EID: 73949106216     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181bbc516     Document Type: Article

References (94)

1. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin of North Am. 2002;16:895-914.
2. Zaoutis TE, Roilides E, Chiou C, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J. 2007;26:723-727.
3. Guardia J, Bourgoignie J, Diego J. Renal mucormycosis in the HIV patient. Am J Kidney Dis. 2000;35:E24.
4. Almyroudis N, Sutton D, Linden P. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006;6:2365-2374.
5. Roilides TZ, Katragkou A. Zygomycosis in neonates: an uncommon but life-threatening infection. Am J Perinatol. 2009;26:565-573.
6. Lopez-Berenstein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985; 151:704-710.
7. Eden OB, Santos J. Effective treatment for rhinopulmonary mucormycosis in a boy with leukaemia. Arch Dis Child. 1979; 54:557-559.
8. Dennis JE, Rhodes KH, Cooney DR, et al. Nosocomial Rhizopus infection (zygomycosis) in children. J Pediatr. 1980; 96:824-828.
9. Cook BA, White CB, Blaney SM, et al. Survival after isolated cerebral mucormycosis. Am J Pediatr Hematol Oncol. 1989; 11:330-333.
10. Cohen-Abbo A, Bozeman PM, Patrick CC. Cunninghamella infections: review and report of two cases of Cunninghamella pneumonia in immunocompromised children. Clin Infect Dis. 1993;17:173-177.
11. Celgow L, Cohn RJ, Sacks AJ. Disseminated mucormycosis: report of a successfully treated immunocompromised child with clinical, radiographic and pathological findings. Pediatr Radiol. 1996;26:131-133.
12. Cantatore-Francis JL, Shin HT, Heilman E, et al. Primary cutaneous zygomycosis in two immunocompromised children. Pediatr Dermatol. 2007;24:257-262.
13. Bhaduri S, Kurrle E, Vanek E, et al. Mucormycosis in the immunocompromised host. Infection. 1983;11:170-172.
14. Eucker J, Sezer O, Lehmann R, et al. Disseminated mucormycosis caused by Absidia corymbifera leading to cerebral vasculitis. Infection. 2000;28:246-250.
15. Gonis G, Starr M. Fatal rhinoorbital mucormycosis caused by saksenaea vasiformis in an immunocompromised child. Pediatr Infect Dis J. 1997;16:714-716.
16. Greenberg RN, Mullane K, Van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126-133.
17. Hutter RVP. Phycomycetous infection (mucormycosis) in cancer patients: a complication of therapy. Cancer. 1958; 12:330-350.
18. Kang CM, Kim HS, Song KS, et al. Localized muscular mucormycosis in a child with acute leukemia. Jpn J Clin Oncol. 1997;27:357-360.
19. Katta R, Bogle MA, Levy ML. Primary cutaneous opportunistic mold infections in a pediatric population. J Am Acad Dermatol. 2005;53:213-219.
20. Kramer BS, Hernandez AD, Reddick RL, et al. Cutaneous infarction. Arch Dermatol. 1977;113:1075-1076.
21. Lopes JO, Pereira DV, Streher LA, et al. Cutaneous zygomycosis caused by Absidia corymbifera in a leukemic patient. Mycopathologia. 1995;130:89-92.
22. Mater A, Al-Sulaiti G, Johnston DL, et al. A 4-year old child with leukemia and an enlarging arm lesion. Can Med Assoc J. 2005;172:332.
23. Mazade MA, Margolin JF, Rossman SN, et al. Survival from pulmonary infection with Cunninghamella bertholletiae: case report and review of the literature. Pediatr Infect Dis J. 1998; 17:835-839.
24. Nevitt PC, Das Narla L, Hingsbergen EA. Mucormycosis resulting in a pseudoaneurysm in the spleen. Pediatr Radiol. 2001;31:115-116.
25. Parkyn T, McNinch AW, Riordan T, et al. Zygomycosis in relapsed acute leukaemia. J Infect. 2000;41:265-282.
26. Parra R, Arnau E, Julia A, et al. Survival after inestinal mucormycosis in acute myelogenous leukemia. Cancer 1986; 58:2717-2719.
27. RyanME, Ochs J. Primary Cutaneous mucormycosis: superficial and gangrenous infections. Pediatr Infect Dis. 1982;1:110-114.
28. Scheld M, Royston D, Harding S, et al. Simultaneous disseminated aspergillosis and zygomycosis in a leukemic patient. South Med J. 1979;72:1325-1328.
29. Sims DG, Scott DJ, Noble TC. Multiple major cerebral artery thromboses with profound thrombocytopenia in acute leukemia. Arch Dis Child. 1976;51:74-77.
30. Suc A, Bremont F, Rubie H, et al. Successful combination of amphotericin therapy and surgical resection for fungal necrotizing pneumoniae in a child receiving chemotherapy for leukemia. Pediatr Pulmonol. 1997;23:386-388.
31. Sundararajan T, Kumar CPG, Menon T, et al. Cutaneous zygomycosis due to Rhizopus oryzae in a patient with acute lymphoblastic leukemia. Mycoses. 2004;47:521-523.
32. TriggME, Comito MA, Rumelhart S. Cutaneous mucor infection treated with wide excision in two childrenwho underwent marrow transplantation. J Pediatr Surg. 1996;31:976-977.
33. Umbert IJ, Su WPD. Cutaneous mucormycosis. J Am Acad Dermatol. 1989;21:1232-1234.
34. Zirak C, Brutus JP, De Mey A. Atypical cause of forearm skin ulceration in a leukaemic child: mucormycosis. A case report. Acta Chir Belg. 2005;105:551-553.
35. Baker RD. Leukopenia and therapy in leukemia as factors predisposing to fatal mycoses. Am J Clin Pathol. 1962;37: 358-373.
36. Barfield RC, Hale GA, Burnette K, et al. Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia. Pediatr Blood Dis Cancer. 2007;48:349-353.
37. Bateman CP, Umland ET, Becker LE. Cutaneous zygomycosis in a patient with lymphoma. J Am Acad Dermatol. 1983; 8:890-894.
38. Becker BC, Schuster FR, Ganster B, et al. Cutaneous mucormycosis in an immunocompromised patient. Lancet Infect Dis. 2006;6:536.
39. Fukushima T, Sumazaki R, Shibasaki M, et al. Successful treatment of invasive thoracopulmonary mucormycosis in a patient with acute lymphoblastic leukemia. Cancer. 1995; 76:895-899.
40. Garces P, Mueller D, Trevenen C. Rinocerebral mucormycosis in a child with leukemia: CT and MRI findings. Pediatr Radiol. 1994;24:50-51.
41. Gilman AL, Serrano A, Skelley J, et al. Successful treatment of pulmonary zygomycosis with posaconzole in a recipient of a haploidentical stem cell transplant. Pediatr Blood Dis Cancer. 2006;47:959-963.
42. Grigull L, Beilken A, Schmid H, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer. 2006;14:783-786.
43. Guitierrez-Diaz A, Hernanz AdP, Larregla S, et al. Orbital Phycomyocis. Ophthalmologica. 1981;182:165-170.
44. Hoover M, Morgan ER, Kletzel M. Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia. Med Pediatr Oncol. 1997;28:268-273.
45. Jain A, Butani L. Severe hyperphosphatemia resulting from high-dose liposomal amphotericin in a child with leukemia. J Pediatr Hematol Oncol. 2003;25:324-326.
46. Koszyca B, Ellis D, Toogood I, et al. Fluconazole in the treatment of pulmonary zygomycosis. Mycoses. 1995;38:277-280.
47. Krauze A, Krenke K, Matysiak M, et al. Fatal course of pulmonary Absidia sp. infection in a 4-year-old girl undergoing treatment for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2005;27:386-388.
48. Kumar L, Singh S, Aggarwal S, et al. Phycomycosis infection in acute leukemia. J Assoc Physicians India. 1989;38:787-789.
49. Lueg EA, Ballagh RH, Forte V. Analysis of the recent cluster of invasive fungal sinusitis at the Toronto hospital for sick children. J Otolaryngol. 1996;25:366-370.
50. Maury S. Successful treatment of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia. Clin Infect Dis. 1998;26:200-202.
51. Morrison VA, McGlave PB. Mucormycosis in a bone marrow transplant population. Bone Marrow Transplant. 1993;11: 383-388.
52. Pearson ADJ, Nesbit ME, Darbyshire PJ, et al. Fungal pneumonias masquerading as thromboses during induction therapy of acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1986;3:153-157.
53. Piccin A, Russell JD, Fleming P, et al. Invasive rhino-maxillary mucormycosis diagnosed before HSCT. Pediatr Blood Dis Cancer. 2006;50:393-395.
54. Risitano AM, Camera A, Chiurazzi F, et al. Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome. Haematologica. 2002;87:ELT36.
55. Ritz N, Ammann RA, Aebischer CC, et al. Failure of voriconazole to cure disseminatd zygomycosis in an immunocompromised child. Euro J Pediatr. 2005;164:231-235.
56. Tan DCL, Hsu LY, Koh LP, et al. Severe conidiobolomycosis complicating induction chemotherapy in a patient with acute lymphoblastic leukaemia. Br J Hematol. 2005;129:447.
57. Vadeboncoeur C, Walton JM, Raisen J, et al. Gastrointestinal mucormycosis causing an acute abdomen in the immunocompromised pediatric patient-three cases. J Pediatr Surg. 1994;29:1248-1249.
58. van Well GT, van Groeningen I, Debets-Ossenkepp YJ, et al. Zygomycete infection following voriconazole prophylaxis. Lancet Infect Dis. 2005;5:594.
59. Wali YA, Al Lamki z, Al Kindi H, et al. Case Report. Successful outcome of invasive nasal sinus zygomycosis in a child with relapsed acute lymphoblastic leukaemia due to liposomal amphotericin B. Mycoses. 2001;44:195-199.
60. Wehl G, Hoegler W, Kropshofer G, et al. Rinocerebral mucormycosis in a boy with recurrent acute lymphoblastic leukemia: long-term survival with systemic antifungal treatment. J Pediatr Hematol Oncol. 2002;24:492-494.
61. Germain GS, Robert A, Ishak M, et al. Infection due to Rhizomucor pusillus: report of four cases in patients with leukemia and review. Clin Infect Dis. 1993;16:640-645.
62. Hernanz AdP, Fereres J, Larregla S, et al. Nosocomial infection by Rhizomucor pusillus in a clinical haematology unit. J Hospital Infect. 1983;4:45-49.
63. Jacobs P, Wood L, Du Toit A, et al. Eradication of invasive mucormycosis-effectiveness of the Echinocandin FK463. Hematol. 2003;8:119-123.
64. Parfrey NA. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine. 1986; 65:113-123.
65. Rangel-Guerra RA, Martinez HR, Saenz C, et al. Rhinocerebral and systemic mucormycosis. Clinical experience with 36 cases. J Neurol Sci. 1996;143:19-30.
66. Wirth F, Perry R, Eskenazi A, et al. Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. J Am Acad Dermatol. 1997;36:336-341.
67. Ryan M, Yeo S, Maguire A, et al. Rhinocerebral zygomycosis in childhood acute lymphoblastic leukaemia. Euro J Pediatr. 2000;160:235-238.
68. Seer Cancer Statistics Review [database online]. Bethesda, MD: National Cancer Institute; 2008. Updated November, 2007.
69. National Cancer Institute Clinical Trials [database online]. Bethesda, MD: National Cancer Institute; 2008. Updated November 18, 2008.
70. Forrest GN, Mankes K. Outcomes of invasive Zygomycosis infections in renal transplant recipients. Transplant Infect Dis. 2007;9:161-164.
71. Singh N, Gayowski T, Singh J, et al. Invasive gastrointestinal Zygomycosis in a liver transplant recipient: case report and review of Zygomycosis in solid-organ transplat recipients. Clin Infect Dis. 1995;20:617-620.
72. Corbel MJ, Eades SM. Factors determining the susceptibility of mice to experimental phycomycosis. J Med Microbiol. 1975; 8:551-564.
73. Waldorf AR, Halde C, Vedros NA. Murine model of pulmonary mucormycosis in cortisone-treated mice. Sabouraudia. 1982; 20:217-224.
74. Waldorf AR, Levitz SM, Diamon RD. In vivo bronchoalveolar macrophage defense against Rhizopus orygae and Aspergillus fumigatus. J Infect Dis. 1984;150:752-760.
75. Waldorf AR, Peter L, Polak A. Mucormycotic infection in mice following prolonged incubation of spores in vivo and the role of spore agglutinating antibodies on spore germination. Sabouraudia: J Med Vet Mycol. 1984;22:101-108.
76. Waldorf AR, Ruderman N, Diamond R. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984; 74:150-160.
77. Siwek GT, Dodgson KJ, de Mogalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:588-590.
78. Sahin B, Paydas S, Cosar E, et al. Role of granulocyte colonystimulating factor in the treatment of mucormycosis. Euro J Clin Microbiol Infect Dis. 1996;15:866-869.
79. Sohail MA, Al Khabori M, Hyder J, et al. Acute fulminant fungal sinusitis: clinical presentation, radiological findings and treatment. Acta Trop. 2001;80:177-185.
80. Gil-Lamaignere C, Hess R, Salvenmoser S, et al. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against Zygomycetes. J Antimicrob Chemother. 2005;55:1016-1019.
81. Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy. 2002;48:78-81.
82. Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of Zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses. 2005; 48:246-250.
83. Uchida K, Nishiyama Y, Yokota N, et al. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot. 2000;53:1175-1181.
84. Barchiesi F, Spreghini E, Santinelli A, et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother. 2007;51:73-77.
85. Dannaoui E, Meis JF, Loebenberg D, et al. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother. 2003;47: 3647-3650.
86. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50:2009-2015.
87. Sun ON, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46:1581-1582.
88. Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002; 46:2310-2312.
89. Reed C, Ibrahim AS, Edwards J, et al. Combination Polyene-Caspofungin Treatment of Rhino-orbital-Cerebral Mucormycosis. Clin Infect Dis. 2008;47:364-371.
90. Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al. Interferon-gamma and granulocyte-macrophage colonystimulating factor augment the activity of polymorphonucelar leukocytes against medically important zygomycetes. J Infect Dis. 2005;191:1180-1187.
91. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23:769-773.
92. Ma B, Seymour JF, Januszewicz H, et al. Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. Leuk Lymphoma. 2001;42:1393-1399.
93. Ibrahim AS, Edwards JEJ, Fu Y, et al. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Agents Chemother. 2006;58:1070-1073.
94. Reed C, Ibrahim A, Edwards JEJ, et al. Deferasirox, an ironchelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50:3968-3969.